I am an orthopaedic surgeon and clinician-scientist based at Sydney’s largest children’s hospital. My goal is to improve treatments for children with traumatic injuries and bone deformity. I have worked in bone research for over 20 years. My current research interests are finding new treatments for drug-resistant bacterial infections, treating genetic bone disease, and developing new medical devices to help children’s bones grow straight.
Determinants Of The Outcomes From Infectious Diseases
Funder
National Health and Medical Research Council
Funding Amount
$585,269.00
Summary
This Fellowship will allow Professor Lloyd to continue clinical and laboratory research in two areas: firstly, in relation to prevention of transmission of hepatitis C infection, and scale up of antiviral treatments, particularly amongst prisoners. Secondly, in studies investigating the biological basis of chronic fatigue states following acute infection or cancer treatment, and also in development of effective treatment for chronic fatigue states.
Delayed bone healing can be a considerable problem in both children and adults. Up to 10% of fractures fail to heal properly. An advanced understanding of the cellular responses in bone repair and their manipulation could improve the lives of many patients with orthopaedic problems. These studies will advance out knowledge of interventions to promote bone healing which could be translated rapidly into clinical care.
Determinants Of The Outcomes From Infectious Diseases
Funder
National Health and Medical Research Council
Funding Amount
$532,630.00
Summary
Professor Lloyd will continue studies of the factors which lead to varied clinical outcomes from common infectious diseases. The outcomes include chronic or persistent illness, rather than prompt recovery. The factors being studied include aspects of the microbes causing the infection; and aspects of the individual suffering from infection, including genetic make-up, immune defences, and treatment responses. The infections studied include common "flu-like" illnesses, as well as hepatitis C.
Melanoma incidence continues to rise & it remains a leading cause of cancer death in young adults. Prevention & early detection are foundations of disease control. Drug treatments for advanced disease have recently begun to extend survival but remain ineffective in many. Utilising the extensive resources of Melanoma Institute Australia (world's largest melanoma treatment centre), this research seeks to improve outcomes of patients with difficult to treat & aggressive melanomas.
Molecular Determinants Of Progression And Treatment Response In Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$467,068.00
Summary
Melanoma, a skin malignancy of pigment cells, is a major Australian health problem and is the commonest cancer in young adults. This project utilises the resources of the world’s largest melanoma treatment service and aims to develop a scientific basis for 1) improved management of individuals at high risk for melanoma progression, and 2) improved treatment of patients with early and disseminated melanoma, in an era of rapid change in the prospects of successfully treating this dangerous cancer.
Using Mouse Models To Identify Better Therapies For Acute Leukemia And Myelodysplasia
Funder
National Health and Medical Research Council
Summary
Despite great advances in the understanding of the genes that cause cancers of the blood, cure rates for patients with acute leukemia, or a more indolent form called myelodyspslaia, has not improved significantly over the last 20 years, with the majority of patients dying from resistant or recurrent disease within 5 years. Our research will use mouse models of acute leukemia and myelodysplasia to identify the critical genetic pathways that drive these diseases and to design and test new therapie ....Despite great advances in the understanding of the genes that cause cancers of the blood, cure rates for patients with acute leukemia, or a more indolent form called myelodyspslaia, has not improved significantly over the last 20 years, with the majority of patients dying from resistant or recurrent disease within 5 years. Our research will use mouse models of acute leukemia and myelodysplasia to identify the critical genetic pathways that drive these diseases and to design and test new therapies that can be taken into clinical trials.Read moreRead less
Translational Research On Malignant Pleural Effusion And Pleural Infection
Funder
National Health and Medical Research Council
Funding Amount
$487,891.00
Summary
I am a leading researcher in pleural effusions (fluid build-up in the chest) from cancer and infection. I run a multicentre clinical trial team to answer important questions directly relevant to patient care, as well as a lab research group with proven record of discovery new treatment targets. This fellowship will capitalize on platforms I have built and determine best approach to remove effusions, understand etiologic roles of the fluid ultimately to find ways to stop fluid from forming.
Advancing Novel Brain Stimulation Treatment For Severe Depression
Funder
National Health and Medical Research Council
Funding Amount
$575,662.00
Summary
The aim of the proposed research is to substantially escalate the development of a range of novel brain stimulation treatments for patients with severe treatment resistant depression (TRD). For example, to expand a substantive research program aimed at further developing methods for the application of repetitive transcranial magnetic stimulation (rTMS) in patients with depression.
I aim to understand the genetics of the epilepsies. Through detailed analysis of different types of epilepsy, and associated features such as intellectual disability and autism, I will describe new epilepsy syndromes, and together with gene discovery, implement novel targeted therapies. This translational program will transform clinical practice by informing diagnosis, prognostic and genetic counseling, and lead to targeted precision therapies to improve outcomes for each patient.